Competition Forces Organon and J&J to Terminate Co-Promotion of Risperdal®
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)
Published: 5 May-2005
DOI: 10.3833/pdr.v2005.i59.686 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Organon terminated the co-promotion agreement with Janssen-Cilag for the antipsychotic drug, Risperdal® (risperidone) owing to the existence of Organon’s potential competiting product Asenapine...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018